Meningococcal meningitis
Meningococcal meningitis is an infection of the membranes surrounding the brain and spinal cord, caused by the bacterium Neisseria meningitidis. The same bacterium can also cause a dangerous bloodstream infection. “Meningitis” is a broader term: other bacteria, viruses and fungi can cause it too. Meningococci can live in a person's nose and throat without causing illness. They spread through respiratory particles and throat secretions, especially during close, prolonged contact. Symptoms usually appear about four days after infection, but the reported range is two to 10 days. Fever, headache, stiff neck and confusion are important warning signs. Bloodstream infection can progress rapidly and may cause a rash that does not fade under pressure. The disease can be fatal and can leave lasting disabilities. Hospital treatment and preventive vaccines are available. Vaccine protection depends on which bacterial group the vaccine covers. Disease occurs worldwide, with recurrent epidemics particularly in Africa's meningitis belt. Crowded settings and large gatherings can increase the risk of spread.
Key facts
| Transmission | Person-to-person through respiratory particles and throat secretions, often from people carrying the bacteria without symptoms; close, prolonged contact facilitates spread. |
|---|---|
| Incubation | Average four days; range two to 10 days, according to WHO's 2023 Nigeria outbreak report. |
| Case fatality | A meningococcal-specific numerical estimate with and without treatment is unknown from the retrieved literature and WHO text. WHO describes invasive meningococcal disease as having high fatality despite prompt treatment. The 7% reported in Nigeria in 2023 covered suspected meningitis of mixed causes, not meningococcal disease alone. |
| Reproduction number | unknown |
| Vaccine | Licensed meningococcal vaccines exist. MenACWY covers groups A, C, W and Y; MenA protects against group A. Protection depends on the groups covered. |
| Treatment | Hospital treatment is available. WHO advises discussing preventive antibiotics with a clinician for household exposure to bacterial meningitis; the retrieved text does not provide a full treatment regimen. |
| Reservoir | Humans, including people carrying the bacteria in the nose and throat without symptoms. |
| Endemic regions | Worldwide; the highest burden and recurrent epidemics occur in the African meningitis belt, from Senegal to Ethiopia. |
Transmission
Meningococci are carried in the human nose and throat. Many carriers have no symptoms, but they can pass the bacteria to others through respiratory particles or throat secretions. Close, prolonged contact, including living with a carrier, makes spread easier. Carriage is usually harmless; occasionally the bacteria invade the body and cause meningitis or bloodstream infection. WHO reports an average incubation period of four days, with a range of two to 10 days. Crowded accommodation and mass gatherings can create opportunities for transmission. The retrieved sources do not establish a reproduction number or a numerical household secondary attack rate.
- Meningitis WHO
- Meningitis - Nigeria WHO · 27 Apr 2023
- Invasive meningococcal disease - Kingdom of Saudi Arabia WHO · 11 Apr 2025
Symptoms and severity
Common meningitis symptoms include fever, headache, a stiff neck, confusion, sensitivity to light, nausea and vomiting. Babies may feed poorly, become unusually inactive or difficult to wake, cry continuously, or develop a bulging soft spot on the head. Meningococcal bloodstream infection can quickly lead to sepsis, a severe illness involving the body's response to infection. Signs include cold hands and feet, fast breathing and low blood pressure. A rash that does not fade under pressure may appear. Lasting problems can include hearing loss, seizures, difficulties with memory or communication, and limb damage after sepsis. WHO describes invasive meningococcal disease as life-threatening even with prompt treatment; the retrieved WHO text does not give a meningococcal-specific treated-versus-untreated fatality estimate.
- Meningitis WHO
- Invasive meningococcal disease - Kingdom of Saudi Arabia WHO · 11 Apr 2025
Treatment and vaccines
Meningococcal disease requires hospital care. In WHO's 2025 report, all 11 confirmed cases treated in Saudi Arabia recovered and were discharged, but that small group does not establish a general survival rate. Preventive vaccines are available, and their coverage matters: MenACWY protects against bacterial groups A, C, W and Y, while MenA targets group A. Other groups can still cause outbreaks after successful group A vaccination campaigns. WHO advises people living with someone who has bacterial meningitis to discuss preventive antibiotics with a doctor or nurse. For Hajj and Umrah, WHO's 2025 notice advised meningococcal vaccination at least 10 days before travel. Travelers should check current destination requirements.
- Invasive meningococcal disease - Kingdom of Saudi Arabia WHO · 11 Apr 2025
- Meningitis WHO
- Meningococcal disease – Nigeria WHO · 24 Mar 2017
Where it occurs
Meningococcal disease occurs worldwide, as individual cases, clusters and epidemics. The highest burden is in sub-Saharan Africa's meningitis belt, stretching from Senegal to Ethiopia. WHO identifies northern Nigeria as part of this high-risk region. Its 2023 Nigeria report describes a dry-season pattern, most commonly from December through June, with a peak in March and April. Outbreak size varies from year to year. Risk also rises where people are crowded together, including displaced-person settings, military camps and mass gatherings. Low vaccination coverage and disrupted access to health care add to the concern. Pilgrimage-associated cases reported in several countries show that travel can connect outbreaks across borders.
- Meningitis WHO
- Meningitis - Nigeria WHO · 27 Apr 2023
- Invasive meningococcal disease - Kingdom of Saudi Arabia WHO · 11 Apr 2025
Recent history
As of 2026-11-22, this site's supplied archive count is 83 events under the broad meningitis key. That is not a count of meningococcal outbreaks alone: returned entries include fungal and pneumococcal meningitis. In Niger, WHO reported 559 meningitis cases from 2022-11-01 through 2023-01-27; 104 of 111 laboratory-confirmed cases were meningococcal group C. WHO's notice dated 2025-04-11 described 17 invasive meningococcal cases associated with religious travel to Saudi Arabia. Its fact sheet reports 21,526 suspected meningitis cases and 971 deaths from 24 belt countries in 2025. Those surveillance totals cover suspected meningitis, not exclusively meningococcal disease. The retrieved notices do not establish the situation throughout 2026.
- Meningitis WHO · 8 Feb 2023
- Invasive meningococcal disease - Kingdom of Saudi Arabia WHO · 11 Apr 2025
- Meningitis WHO
- Outbreak of suspected fungal meningitis associated with surgical procedures performed under spinal anaesthesia – the United States of America and Mexico WHO Disease Outbreak News · 1 Jun 2023
What to watch
More concerning signals include rising case numbers, clusters in new regions, and travel-linked cases appearing across several countries. Human-to-human spread is already established; the important change would be evidence of wider or sustained transmission. Laboratory identification of the bacterial group matters because vaccine coverage differs. Low vaccine uptake, shortages that delay vaccination campaigns, and disrupted health services could weaken outbreak control. Antibiotic resistance also deserves attention: WHO reported ciprofloxacin-resistant strains in three pilgrimage-associated cases in 2024. This does not mean all treatment antibiotics have failed, but it can affect prevention choices. For individuals, fever with stiff neck, confusion, or signs of rapidly worsening bloodstream infection warrants urgent medical assessment.
- Invasive meningococcal disease - Kingdom of Saudi Arabia WHO · 11 Apr 2025
- Meningitis - Nigeria WHO · 27 Apr 2023
- Meningitis WHO